Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Starling Oncology, Inc.TOI · Entity 5327 | Chief Financial Officer | March 21, 2022 | March 30, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Starling Oncology, Inc.
Report date March 21, 2022 · Filed March 30, 2022 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.09 · Expires 2032-03-21 | Direct | 162,891 |
Reported balance
After 2022-03-21 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2022-03-21 · Grant · Acquired 162,891 · Balance 162,891 F1: The stock options vest as to 1/3rd of the options granted on the second anniversary of November 12, 2021 (the "Vesting Commencement Date"), with the remaining options vesting in four equal annual installments beginning on the third anniversary of the Vesting Commencement Date, with all options becoming vested on the sixth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest as to 1/3rd of the options granted on the second anniversary of November 12, 2021 (the "Vesting Commencement Date"), with the remaining options vesting in four equal annual installments beginning on the third anniversary of the Vesting Commencement Date, with all options becoming vested on the sixth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 21, 2022 Filed Mar 23, 2022 23:37 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantStock Option (right to buy) · Derivative | 26,062 | $0.00 Strike: $7.09 | $0.00 |
DisclosureSEC source: 0001628280-22-007103 · wf-form4_164807863846129.xml · derivative · entry 2 Dalgleish Scott · CIK 0001891053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,062 Underlying: Common stock · 26,062 shares Expires 2032-03-21 F2 · derivative.exercise_date: The stock options vest as to 1/3rd of the options granted on the second anniversary of the Vesting Commencement Date, with the remaining options vesting in four equal annual installments beginning on the third anniversary of the Vesting Commencement Date, with all options becoming vested on the sixth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 23:37 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon stock | 32,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-007103 · wf-form4_164807863846129.xml · nonDerivative · entry 1 Dalgleish Scott · CIK 0001891053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,008 F1 · shares: Represents RSUs with 1/3rd of the RSUs vesting on the second anniversary of November 12, 2021 ("the Vesting Commencement Date"), with the remaining RSUs vesting in four equal annual installments beginning on the third anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the sixth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. F1 · price: Represents RSUs with 1/3rd of the RSUs vesting on the second anniversary of November 12, 2021 ("the Vesting Commencement Date"), with the remaining RSUs vesting in four equal annual installments beginning on the third anniversary of the Vesting Commencement Date, with all RSUs becoming vested on the sixth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
| March 21, 2022 Filed Mar 30, 2022 00:10 UTC Amendment | Starling Oncology, Inc. TOI · Entity 5327 | GrantStock Option (right to buy) · Derivative | 162,891 | $0.00 Strike: $7.09 | $0.00 |
DisclosureSEC source: 0001628280-22-007760 · wf-form4a_164859902956940.xml · derivative · entry 1 Dalgleish Scott · CIK 0001891053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,891 Underlying: Common stock · 162,891 shares Expires 2032-03-21 F1 · derivative.exercise_date: The stock options vest as to 1/3rd of the options granted on the second anniversary of November 12, 2021 (the "Vesting Commencement Date"), with the remaining options vesting in four equal annual installments beginning on the third anniversary of the Vesting Commencement Date, with all options becoming vested on the sixth anniversary of the Vesting Commencement Date, subject to continued service with the Company through such vesting dates. Read SEC document |
| November 12, 2021 Filed Nov 17, 2021 02:56 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantStock Options (right to buy) · Derivative | 350,876 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001104659-21-140226 · tm2132979d17_4seq1.xml · derivative · entry 4 Dalgleish Scott · CIK 0001891053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,876 Underlying: Common Stock · 350,876 shares Expires 2030-11-16 F5 · kind: These stock options were received in connection with the Business Combination in exchange for performance based stock options to acquire shares of Old TOI, and reflect the holder's allocated share of the stock consideration pursuant to the Merger Agreement.These options vest monthly for 36 months following November 12, 2021, the date of the closing of the Business Combination, subject to continued employment through the vest date. F5 · derivative.exercise_date: These stock options were received in connection with the Business Combination in exchange for performance based stock options to acquire shares of Old TOI, and reflect the holder's allocated share of the stock consideration pursuant to the Merger Agreement.These options vest monthly for 36 months following November 12, 2021, the date of the closing of the Business Combination, subject to continued employment through the vest date. Read SEC document |
| November 12, 2021 Filed Nov 17, 2021 02:56 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantStock Options (right to buy) · Derivative | 261,023 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001104659-21-140226 · tm2132979d17_4seq1.xml · derivative · entry 3 Dalgleish Scott · CIK 0001891053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,023 Underlying: Common Stock · 261,023 shares Expires 2030-11-16 F4 · kind: These stock options were received in connection with the Business Combination in exchange for time-vested stock options to acquire shares of Old TOI, and reflect the holder's allocated share of the stock consideration pursuant to the Merger Agreement. These options vest as to 1/4th of the total number of shares subject to the option on the first anniversary of November 16, 2020 (the "Original Grant Date"), and as 1/36th of the total number of shares monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Original Grant Date, subject to continued employment through the vest date. F4 · derivative.exercise_date: These stock options were received in connection with the Business Combination in exchange for time-vested stock options to acquire shares of Old TOI, and reflect the holder's allocated share of the stock consideration pursuant to the Merger Agreement. These options vest as to 1/4th of the total number of shares subject to the option on the first anniversary of November 16, 2020 (the "Original Grant Date"), and as 1/36th of the total number of shares monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Original Grant Date, subject to continued employment through the vest date. Read SEC document |
| November 12, 2021 Filed Nov 17, 2021 02:56 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 71,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-140226 · tm2132979d17_4seq1.xml · nonDerivative · entry 2 Dalgleish Scott · CIK 0001891053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,916 F2 · price: These shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the Business Combination, subject to continued employment at such time. F1 · acquired: On November 12, 2021, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as June 28, 2021, by and among DFP Healthcare Acqusitions Corp. ("DFP"), Orion Merger Sub I, Inc. ("First Merger Sub"), Orion Merger Sub II, LLC ("Second Merger Sub"), and TOI Parent, Inc. ("Old TOI"), First Merger Sub merged into Old TOI, with Old TOI being the surivivng corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the "Business Combination"). Upon consummation of the Business Combination, each issued and outstanding share of common stock of Old TOI was automatically cancelled and the holder thereof was entitled to receive its allocable share of cash and stock consideration pursuant to the Merger Agreement. F3 · acquired: The shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $15.00 per share for 20 days within any 30 consecutive trading days for the three-year period following the closing of the Business Combination, subject to continued employment at such time. Read SEC document |
| November 12, 2021 Filed Nov 17, 2021 02:56 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 47,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-140226 · tm2132979d17_4seq1.xml · nonDerivative · entry 1 Dalgleish Scott · CIK 0001891053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,566 F2 · price: These shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the Business Combination, subject to continued employment at such time. F1 · acquired: On November 12, 2021, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as June 28, 2021, by and among DFP Healthcare Acqusitions Corp. ("DFP"), Orion Merger Sub I, Inc. ("First Merger Sub"), Orion Merger Sub II, LLC ("Second Merger Sub"), and TOI Parent, Inc. ("Old TOI"), First Merger Sub merged into Old TOI, with Old TOI being the surivivng corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the "Business Combination"). Upon consummation of the Business Combination, each issued and outstanding share of common stock of Old TOI was automatically cancelled and the holder thereof was entitled to receive its allocable share of cash and stock consideration pursuant to the Merger Agreement. F2 · acquired: These shares were received in connection with the Business Combination and represent restricted earn-out shares subject to forfeiture and unvested until such time the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the Business Combination, subject to continued employment at such time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.